Advertisement
Heart, Lung and Circulation

Update on the Diagnosis and Management of Hypertrophic Cardiomyopathy

Published:October 25, 2017DOI:https://doi.org/10.1016/j.hlc.2017.10.007
      This standard of practice document briefly outlines the current approach to the diagnosis and management of hypertrophic cardiomyopathy (HCM). The supporting levels of evidence are reported in both the American Heart Association HCM guidelines [
      • Gersh B.J.
      • Maron B.J.
      • Bonow R.O.
      • Dearani J.A.
      • Fifer M.A.
      • Link M.S.
      • et al.
      2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
      ] and the European Society of Cardiology HCM guidelines [
      • Elliott P.M.
      • Anastasakis A.
      • Borger M.A.
      • Borggrefe M.
      • Cecchi F.
      • Charron P.
      • et al.
      2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
      ]. There is also a detailed recent review of HCM for further reference [
      • Maron B.J.
      • Ommen S.R.
      • Semsarian C.
      • Spirito P.
      • Olivotto I.
      • Maron M.S.
      Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.
      ]. Since the last CSANZ HCM guidelines in 2011, the main changes relate to emerging sudden death risk factors such as the amount of myocardial fibrosis, the development of an HCM Risk Score, and more careful consideration of cascade genetic testing in asymptomatic relatives without an HCM phenotype.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gersh B.J.
        • Maron B.J.
        • Bonow R.O.
        • Dearani J.A.
        • Fifer M.A.
        • Link M.S.
        • et al.
        2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2011; 124: 2761-2796
        • Elliott P.M.
        • Anastasakis A.
        • Borger M.A.
        • Borggrefe M.
        • Cecchi F.
        • Charron P.
        • et al.
        2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
        Eur Heart J. 2014; 35: 2733-2779
        • Maron B.J.
        • Ommen S.R.
        • Semsarian C.
        • Spirito P.
        • Olivotto I.
        • Maron M.S.
        Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.
        J Am Coll Cardiol. 2014; 64: 83-99
        • Semsarian C.
        • Ingles J.
        • Maron M.S.
        • Maron B.J.
        New perspectives on the prevalence of hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2015; 65: 1249-1254
        • O’Mahony C.
        • Jichi F.
        • Pavlou M.
        • Monserrat L.
        • Anastasakis A.
        • Rapezzi C.
        • et al.
        A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
        Eur Heart J. 2014; 35: 2010-2020
        • Maron B.J.
        • Maron M.S.
        • Semsarian C.
        Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.
        J Am Coll Cardiol. 2012; 60: 705-715
        • Ingles J.
        • Doolan A.
        • Chiu C.
        • Seidman J.
        • Seidman C.
        • Semsarian C.
        Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling.
        J Med Genet. 2005; 42: e59
        • Maron B.J.
        • Maron M.S.
        • Semsarian C.
        Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors.
        Heart Rhythm. 2012; 9: 57-63
        • Ingles J.
        • Semsarian C.
        The value of cardiac genetic testing.
        Trends Cardiovasc Med. 2014; 24: 217-224
        • Ingles J.
        • Sarina T.
        • Yeates L.
        • Hunt L.
        • Macciocca I.
        • McCormack L.
        • et al.
        Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy.
        Genet Med. 2013; 15: 972-977
        • Ingles J.
        • Semsarian C.
        Conveying a probabilistic genetic test result to families with an inherited heart disease.
        Heart Rhythm. 2014; 11: 1073-1078
        • Maron B.J.
        • Spirito P.
        • Shen W.K.
        • Haas T.S.
        • Formisano F.
        • Link M.S.
        • et al.
        Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
        JAMA. 2007; 298: 405-412
        • Ingles J.
        • Yeates L.
        • Semsarian C.
        The emerging role of the cardiac genetic counselor.
        Heart Rhythm. 2011; 8: 1958-1962